Rob Anstey

VP, Business Development

Rob joined Kallyope in July 2016 as VP, Business Development with responsibility for the company’s business development, finance, and legal functions. He was most recently at Ultragenyx Pharmaceutical, a biotech focused on rare genetic diseases, where his roles included Senior Director, Business Development and Director, Strategic Planning & Investor Relations. Earlier in his career, he was Associate Director, Strategic Planning & Corporate Development for Agenus Inc., a biotech focused on immuno-oncology. During his career, he has led or supported multiple licensing and collaborative partnerships with pharmaceutical, biotech, and academic organizations, including Novo Nordisk and Takeda Pharmaceuticals, and has raised more than $900 million via private and public financings. Rob received his M.B.A. with distinction from Northwestern University’s Kellogg School of Management and his B.S. cum laude in Economics and International Business from NYU’s Stern School of Business.